Ab btract. The effects of experimental nephrosis in rats, produced by puromycin aminonucleoside, include an elevation of plasma levels of all lipoprotein density classes and the appearance of high density lipoprotein (HDL) rich in apoprotein (apo) A-I and deficient in apo A-IV and apo E. The hyperlipoproteinemia is associated with an increase in hepatic synthesis of lipoproteins. The possible role of decreased very low density lipoprotein (VLDL were obtained from nonfasting animals by ultracentrifugation at d 1.006 and included chylomicrons) catabolism and its relationship to the apolipoprotein composition of nephrotic high density lipoproteins (1.063 < d < 1.210, or 1.072 < d < 1.210 [HDL]) was explored.
Introduction
The nephrotic syndrome is associated with increased plasma concentrations of lipoproteins and an increased hepatic lipoprotein synthesis rate (1, 2) . A delay in triglyceride clearance due to decreased very low density lipoprotein (VLDL' were obtained from nonfasting animals by ultracentrifugation at d 1.006 and included chylomicrons) catabolism has been reported (3) (4) (5) , which may contribute substantially to the hyperlipemia. We have previously reported studies of high density lipoprotein (HDL) catabolism in nephrotic rats, and have noted the deficiency of apoprotein (apo) A-IV and apo E in nephrotic HDL (6) (7) (8) . The present investigation was undertaken to determine whether the abnormal apolipoprotein composition of nephrotic HDL could be related to changes in VLDL catabolism. Our previous studies of VLDL catabolism in normal rats (9) have shown that, of the two main forms of apo B in rat plasma, the smaller (apo B of lower molecular weight [apo BL]) is removed at a more rapid rate than the larger (apo B of higher molecular weight [apo BH]). For this differential catabolic rate to occur in the isolated perfused liver, prior exposure of the VLDL to lipase action is required 1 . Abbreviations used in this paper: apo, apoprotein; apo A-I, apo A-IV, apo B, apo C, apo C-II, apo E, apoproteins A-I, A-IV, B, C, C-II, and E; apo BL, apo B of lower molecular weight; apo BH, apo B of higher molecular weight; HDL, high density lipoproteins (1.063 < d < 1.210, or 1.072 < d < 1.210); IDL, intermediate density lipoproteins (1.006 < d < 1.020); PAGE, polyacrylamide gel electrophoresis; VLDL, very low density lipoproteins that were obtained from nonfasting animals by ultracentrifugation at d 1.006 and included chylomicrons. (10) . In the present experiments, we have injected '251I-VLDL and followed the disappearance of labeled apoproteins from plasma and have measured the concentrations of the remaining apoproteins in all of the lipoprotein density classes. We also measured heparin-releasable lipoprotein lipase and hepatic lipase activities. Our results provide evidence that decreased lipolysis of VLDL in nephrosis accounts for the abnormal apoprotein composition of HDL.
Methods
Induction of nephrosis. Male Fischer 344 rats that weighed between 200 and 250g were injected intraperitoneally with 120 mg/kg of puromycin aminonucleoside (Sigma Chemical Co., St. Louis, MO). They were studied 7-9 d after injection, and only rats with accumulation of ascites fluid were used. Nephrosis was confirmed by measurements of levels of serum cholesterol and albumin. Rats were fed standard laboratory chow. Pair feeding was carried out by allowing control rats access to the same weight of chow that was eaten by the nephrotic rats the previous day.
Preparation of 125Ij VLDL and plasma lipoprotein fractionation. In the experiments in which heparin was injected in vivo, the VLDL (d < 1.006) was prepared from rats in which 10% sucrose was added to the drinking water. The lipoprotein was labeled with 1251 according to the procedure described by Bilheimer et al. ( 11) and contained 16% of the label in the protein moiety. All other 251I-VLDL that was used in this study were obtained from rats fed a sucrose-casein special diet, labeled as previously described (9) , and contained 72% of the label in the protein moiety. The difference in protein labeling may be related to the higher content of unsaturated fatty acids in ordinary chow diets and to a lower protein concentration that was used in the labeling procedure. Plasma lipoproteins were isolated by sequential density ultracentrifugation of densities of 1.006, 1.020, 1.063, and 1.210 as previously described (2) , using a Ti-50 rotor in a Beckman L3-50 ultracentrifuge (Beckman Instruments Inc., Palo Alto, CA) at 50C. The top milliliter from each centrifuge tube was removed and dialyzed overnight against 0.15 M NaCl-0.002 M EDTA, pH 7.4, at 5°C, using dialysis tubing with an exclusion of 3,500 mol wt before analysis.
Apoprotein analysis. The measurement of apoprotein concentrations in isolated lipoproteins was carried out by SDS-polyacrylamide gel electrophoresis (PAGE), essentially according to Swaney et al. (12) , as previously described (2) . Radioassay of '25l-labeled apoproteins was performed according to the method of Sparks and Marsh (13) . Fractions of apoproteins that were obtained by treatment of whole plasma or isolated dialyzed lipoproteins were incubated 3 min at 100°C with an equal volume of a solution that contained 10% SDS, 10% glycerol, 10% 2-mercaptoethanol, and 0.1 M Tris (pH 7.0). The apoproteins were separated by SDS-agarose column chromatography (13), and the radioactivity was determined using a Beckman gamma spectrometer (Beckman Instruments Inc.) with a counting error of <5%. Lipoproteins were delipidated before analysis by the chloroform-methanol-ether procedure of Lux et al. (14 
Results
Nephrosis was confirmed in puromycin aminonucleoside-injected rats by the presence of plasma cholesterol levels > 250 mg/dl. Plasma albumin concentrations averaged 3.41±0.17 g/ dl (n = 7) in controls and 1.46±0.07 g/dl (n = 7) in nephrotics.
The first series of experiments were designed to answer the question of whether or not there was a decrease in the removal of total apo B, or of the individual B apoproteins in nephrotic rats. At 3 min after the injection of '25I-VLDL, the distribution of label among apoproteins in whole serum of nephrotics was not different from that of the injected material (data not shown). In controls, the apo BL component of plasma was less than that of nephrotics at 3 min. By 30 min, the ratio of labeled BL to BH decreased from 4.0 to 1.4 in control rats, which was in agreement with our earlier observations (9) , while in the nephrotics the labeling ratio was unchanged. The injection of heparin did not produce a further decrease in the apo BL/apo BH labeling ratio in either controls or nephrotics (Table I ).
Significant changes in the lipid concentrations in plasma were seen after heparin injection in both groups of animals as shown in Table II . Triglyceride levels were decreased by 58% (in paired experiments) in the nephrotic rats while in the controls they decreased by 77%. No significant changes in plasma phospholipid or cholesterol levels were observed. Total free fatty acid levels were not different from normal, but after heparin injection they rose in both groups of animals, with the nephrotic rats showing a greater increase (Table II) . Table  III than albumin in the nephrotic plasma, which was a situation Table V shows the effects of heparin injection on the opposite to that seen in the controls. labeled apolipoprotein distribution in control and nephrotic
When the plasma was separated into individual density rats. The amount of labeled apo C that was associated with classes after the injection of 125I-VLDL, as shown in Table IV, HDL increased from 8 to 27% of total labeled apo C after significant shifts of labeled lipid from VLDL to all of the injection of 123I-VLDL into control rats that were not given higher density ranges were seen in normal rats when heparin heparin. This increase was somewhat less (to 20%) in the was injected, with the most striking changes seen in the nephrotic rats. After heparin, <10% of labeled apo C remained intermediate density lipoprotein ( (Table II) , these shifts in density were heparin, and a further appearance of large amounts of label in probably due to particle changes that resulted from triglyceride LDL. In the nephrotics, these changes were greatly diminished. hydrolysis. In the nephrotic rats, heparin produced a much
No apo BH and only 4% of apo BL appeared in LDL even smaller decline in VLDL-associated lipid label with shifts into after heparin. For apo E, 9% appeared in HDL at 30 min in the higher density classes. normals, and this amount was increased fourfold after heparin. Similar changes occurred for apo E in the nephrotics, but they
were not as pronounced (Table V) . Since heparin injection increased the amount of labeled apo E that appeared in nephrotic rat HDL, we also examined the apoprotein composition of the HDL by SDS-PAGE. As indicated in Table VI and Fig. 1 , an increase in the content of apo A-IV, as well as apo E, was seen. Because the concentration of apo E that was present in the d < 1.063 fraction in nephrotic plasma was high, we were able to test the assumption that the appearance of apo E in nephrotic HDL after heparin injection could be duplicated in vitro by the addition of lipoprotein lipase to whole serum. The results ofthis experiment are given in Table VII and Fig. 1 , where it can be seen that the amounts of both apo E and apo C increased in HDL and that these apoproteins stayed with HDL after recentrifugation.
The lipoprotein lipase and hepatic lipase activities released into the plasma after the injection of heparin were also The numbers in parentheses represent the number of individual samples which were pooled before ultracentrifugation. In whole plasma, 85±3% of the total lipid label was in phospholipid, as determined by thin-layer chromatographic analysis (42).
* Samples of '251I-VLDL (uninjected) were added to whole rat plasma and subjected to sequential density ultracentrifugation as described in Methods. (3) 24.8±0.87t * Livers were perfused with medium that contained 40 U heparin/ml as described in Methods. Lipoprotein lipase was measured as the fraction of total lipase activity inhibited by I M NaCI. Heparin for experiment 3 was obtained from Sigma Chemical Co.; heparin for exps. 1 and 2 was obtained from Organon, Inc. Assay conditions are described in Methods. Lipoprotdin lipase was estimated as the difference between total activity and that which was inhibited by I M NaCl (15) . * Significantly different from the mean of the normal rats (P < .025). perfused rat livers. Further evidence for decreased lipolysis was obtained by following the disappearance of labeled VLDL from plasma after intravenous injection. Three parameters that were related to lipolysis were measured-the apo BLJapo BH labeling ratio, the distribution of labeled apoproteins other than apo B, and the distribution of labeled lipid (mainly phospholipid) in the lipoprotein density classes that remained in plasma after 30 min. Whereas the apo BLjapo BH labeling ratio declined from 4.0 to 1.4 in the control rats, there was no significant change in the ratio in the nephrotic rats, even after the injection of heparin. Liver perfusion studies (10) have shown that VLDL lipolysis is necessary for the differential catabolism of apo BL compared with apo BH, although the extent of lipolysis that is required has not been precisely determined. In the normal rats, 30 min after injection of labeled VLDL, 17% of the total remaining labeled phospholipid in plasma appeared in HDL and 12% in the d > 1.21 fraction, while in the nephrotic rats only 3% of the phospholipid label was in HDL and 0.5% was in the d > 1.21 fraction.
When heparin was injected into control and nephrotic rats, changes in the distribution of labeled apoproteins were observed at 30 min that complement the measurements of plasma lipase activity (measured at 10 min). In normal animals, heparin injection increased the amount of labeled apo C that was associated with HDL from 27 to 84%, due to its release from VLDL during the accelerated lipolysis. Much less occurred in the nephrotic rats; the percentage of total labeled apo C that was associated with HDL increased from 20 to 42%. After heparin, 31% of apo BH and 46% of apo BL were found in LDL in normal rats, while no apo BH and only 4% of apo BL were found in LDL in nephrotic rats, which again suggests decreased fractional lipolysis. At 30 min in the normal rats, considerable amounts of these two apolipoproteins were found in IDL (52 and 41%, respectively, for apo BH and apo BL), while there was very little (9 and 5%) in the IDL of the nephrotic plasma. We conclude that in spite of the decreased total triglyceride content of the plasma after the injection of heparin in the nephrotic rats, the resulting increase in average VLDL particle density was insufficient to cause a large shift into the d < 1.02 range. We did not separate chylomicrons from VLDL in these animals, so that a portion of the decline in total mass of plasma triglycerides may have been due to loss of chylomicron triglyceride. Finally, in these tracer experiments, the behavior of labeled apo E was qualitatively similar to that of apo C. In the nephrotic rats after heparin, labeled apo E shifted from VLDL to HDL, although less apo E appeared in nephrotic HDL than in controls. The most striking differences were seen in LDL, where the percentages of apo E were 14% (controls) compared with 3% (nephrotics). The changes in labeled apo E distribution in HDL were accompanied by changes in mass distribution (Table VI) , and they were also observable by the direct addition of a purified lipoprotein lipase preparation to whole nephrotic plasma.
These observations provide strong evidence that apo E appears in the rat HDL density class as a consequence of lipolysis of triglyceride-rich lipoproteins. The work of Weisgraber et al. (28) and of Blum (29) has clearly shown the ability of apo E to transfer from VLDL to HDL. In explaining the lack of apo E in nephrotic HDL as due to a failure of VLDL lipolysis, we must take into account the fact that perfused livers of nephrotic rats secrete appreciable amounts of apo E in the HDL density range (2) . Our present hypothesis is that this apo E does not remain with nascent HDL after the latter reaches the plasma, but further experiments will be required to substantiate this point.
Rat HDL contains appreciable amounts of apo A-IV, which, in contrast to hepatically derived apo E, is largely an intestinal product (30) . A decreased chylomicron lipolysis rate in nephrosis would therefore lead to an apo A-IV deficient HDL if apo A-IV behaved in a fashion similar to apo C and apo E. Our experiments with the in vivo injection of heparin in nephrotic rats suggest that this is so. However, much of plasma apo A-IV is in the d > 1.21 fraction (31), and this lipid-poor apo A-IV might also be a precursor of the apo A-IV of HDL. Because of its small size compared with that of the triglyceride-rich lipoproteins, it might be lost in the urine of the nephrotic rat. The fact that we were able to demonstrate an increase in the apo A-IV content of nephrotic HDL in vivo but not in vitro upon the addition of lipoprotein lipase may be explained by the low apo A-IV concentration in the total d < 1.006 fraction of nephrotic plasma. Presumably, in vivo the rapid metabolism of chylomicrons provides a continuous supply of apo A-IV. It is pertinent that in streptozotocindiabetic rats that show decreased triglyceride and VLDL catabolism (32) , the HDL is also deficient in apo A-IV and apo E (33, 34).
The conclusion that there is decreased fractional VLDL lipolysis in nephrosis is supported by the experiments presented here. The question then arises as to the mechanism. The lipase reactions that are responsible require not only the enzyme, but also, in the case of lipoprotein lipase, a cofactor, apo C-II, and an acceptor for the fatty acids that are formed, which is normally albumin. Furthermore, if catabolism is to proceed beyond the remnant stage, there must be an adequate hepatic capacity for remnant removal, since the liver is the main site of chylomicron and VLDL remnant uptake (36) . With regard to the enzymes involved, lipoprotein lipase and hepatic lipase, our experiments are compatible with the idea that the amount of these enzymes may be decreased, but they do not rule out the possible presence of endogenous plasma inhibitors of lipase activity, nor the possible absence of lipase activators such as those described by Kashyap et al. (36) and Staprans et al. (37) . The C apoproteins are present in large amounts in nephrotic plasma (8) , and the lack of apo C-II would not seem to be a likely explanation for the greatly decreased VLDL fractional catabolic rate. Although puromycin aminonucleoside itself may have contributed to the decreased lipase activity, we consider that unlikely. The rats were studied 7-8 d after its administration, by which time any direct effects of puromycin aminonucleoside on lipase activity would be minimal.
The role of fatty acids as inhibitors of lipase reaction rates, and the role of albumin as a free fatty acid acceptor, can be addressed on the basis of our measurements of fatty acid levels in the various plasma density classes and in whole serum. In nephrotic rats that were fed ad lib., and killed at the same time of day as the controls, we did not find significant differences in the total free fatty acid levels, which is in agreement with earlier studies in humans (38) . From the levels of albumin that were found, the free fatty acid to albumin molar ratio can be calculated. Assuming that all of the free fatty acids were bound to albumin, the molar ratio would be 0.5 in normals and 1.0 in nephrotics. This molar ratio is not high enough to produce a significant slowing in the rate of lipolysis (39) . After the injection of heparin, the free fatty acid content at 30 min was increased 2.6-fold in controls and 5.2-fold in nephrotics. However, because of the high plasma levels of lipoproteins and the low levels of albumin, most of these fatty acids were not bound to albumin but to the lipoproteins themselves. Based on the distribution data shown in Table III , which are similar to the results in human nephrotic syndrome (38) , the calculated free fatty acid to albumin molar ratio was 0.97 for controls and 0.76 for nephrotics, which suggests that even after heparin, saturation of binding sites for free fatty acids on the albumin molecule is not a likely cause for inhibition of lipolysis. The question of whether the increased amounts of free fatty acids in the VLDL fraction could contribute to a slowing of the rate of lipolysis may be examined by calculating the free fatty acid to triglyceride ratio based on the data in Tables II and III . Without heparin injection, the total free fatty acid levels are low enough that even if 25% were in VLDL, they would only amount to 0.3% of the triglyceride in nephrotic rats and 0.1% in normal rats. After heparnn, the free fatty acids amounted to 2.7% of the triglyceride in nephrotics and 1.0% in normals, which may have contributed to an eventual slowing of the lipolytic rate.
Perhaps the most difficult question to answer on the basis of the present work is the effect of increased plasma VLDL concentration per se, as a result of increased hepatic synthesis (2), on the catabolic rate. At least two questions must be answered. First, are the endothelial-bound lipases saturated at a steady state concentration of VLDL which is sevenfold increased over normal? If they are, then the fractional catabolic rate would be decreased and we might not be able to observe a significant change in the apo BJapo BH labeling ratio at 30 min because too small a percentage of the total pool was turned over. We do not believe this was the case. Although the apo BLJapo BH ratio was greatly reduced at 30 min in the controls, we have not observed significant changes in this ratio in nephrotics even at 60 min (data not shown), which is at least seven times the normal half-life of rat VLDL apo B (9 
